SC
DNA icon

Sculptor Capital’s Ginkgo Bioworks DNA Stock Holding History

Sculptor Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,933
Closed -$807K – 585
2022
Q4 		$807K Hold
11,933
– – 0.01% 414
2022
Q3 		$1.49M Buy
+11,933
New +$1.42M 0.02% 552

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Sculptor Capital's DNA Position: Q1 2023 in Review

Sculptor Capital sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 11,933 shares — an estimated $807K sold.

Sculptor Capital first reported a position in DNA in Q3 2022 and held it in 2 quarters. The position peaked at $1.49M in Q3 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

  • Sculptor Capital reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
  • Sculptor Capital sold 11,933 Ginkgo Bioworks shares in Q1 2023, an estimated $807K.
  • Sculptor Capital first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 2 quarters.
  • Sculptor Capital's Ginkgo Bioworks position peaked at $1.49M in Q3 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.